10月14日，外媒报道称著名的投资机构黑石集团和德太投资（TPG Capital）正考虑联手收购全球眼科巨头博士伦。

A Manhattan federal court jury handed down the verdict after Valeant announced it will change its name to Bausch Health Companies Inc, in a bid to rebuild its reputation after a string of scandals.

最近，拥有171年历史，潜在客户约10亿人次的眼科巨头博士伦，被端上了“餐桌”：黑石集团和 TPG或将联手出价130亿美元至140亿美元（至多人民币1000亿元），从博士康手中将其买下。

10月14日，外媒报道称著名的投资机构黑石集团和德太投资（TPG Capital）正考虑联手收购全球眼科巨头博士伦。

The eye care division, spun out of Bausch Health (formerly Valeant) in 2020, is working with Goldman Sachs to gauge interest from potential buyers, with private equity firms expected to be among ...

Bausch Health is the former Valeant, a company that grew rapidly thanks to a string of acquisitions that left it with $21 billion in debt, almost $10 billion of which will mature in 2027.

Bausch Health Companies Inc (BHC) reports robust revenue growth and strategic initiatives, while navigating ongoing legal and market challenges.

The eye care business — which was carved out of Bausch Health, formerly known as Valeant, in 2020 — is working with advisers from Goldman Sachs to test interest from potential buyers ...

"Improving health outcomes is at the core of our business at Valeant," said Joseph C. Papa, chairman and chief executive of Valeant. "We're excited that Bausch + Lomb and IBM will team up to ...

Of note, Bausch + Lomb is the eye-care subsidiary of Bausch Health Companies, which was formerly known as Valeant Pharmaceuticals. Valeant got into trouble nearly a decade ago after using debt to ...

Bausch Health (NYSE: BHC) stock has been on a wild ride recently, with a dramatic surge in value over the last month. The catalyst for this surge is a wave of rumors suggesting that Bausch + Lomb ...

https://www.tipranks.com/news/company-announcements/i-mab-biopharmas-strategic-us-transition-and-pipeline-focus Bullish option flow detected in Bausch Health (BHC ...